Literature DB >> 9740153

Cutaneous necrosis from calcific uremic arteriolopathy.

T Coates1, G S Kirkland, R B Dymock, B F Murphy, J K Brealey, T H Mathew, A P Disney.   

Abstract

Calcific uremic arteriolopathy (calciphylaxis) is an uncommon complication of chronic renal failure that is associated with high morbidity and mortality. We report 16 patients (13 female) who presented between 1985 and 1996. All patients developed painful livido reticularis that progressed to cutaneous necrosis and ulceration (11 cases on the proximal extremities and five cases on the distal extremities). Two patients with predominately distal leg disease survived; the cause of death in the other 14 patients was sepsis (six patients), withdrawal from dialysis (three), cardiac arrest (three), and gastrointestinal hemorrhage (two). Mesenteric ischemia from intestinal vascular calcification occurred in two cases. Clinical factors identified included the use of warfarin therapy in seven cases and significant weight loss (>10% body weight) in seven cases in the 6 months preceding the development of calcific uremic arteriolopathy. Skin pathology was studied in 12 cases, with all showing calcific panniculitis and small vessel calcification. Electron microscopic spectral analysis of the mineral content of the calcific lesions in the subcutaneous tissue showed only calcium and phosphorous. In two cases, substitution of low molecular weight heparin for warfarin therapy resulted in clinical improvement. Current theories of pathogenesis and treatment are reviewed. This study confirms the high morbidity and mortality of calcific uremic arteriolopathy producing ischemic tissue necrosis while drawing attention to significant weight loss and warfarin therapy as risk factors for the development of ischemic tissue necrosis. Hyperbaric oxygen therapy warrants further study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740153     DOI: 10.1053/ajkd.1998.v32.pm9740153

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  57 in total

Review 1.  Vascular and valvar calcification: recent advances.

Authors:  A Farzaneh-Far; D Proudfoot; C Shanahan; P L Weissberg
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 2.  Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.

Authors:  Sharon M Moe; Neal X Chen
Journal:  Pediatr Nephrol       Date:  2003-10       Impact factor: 3.714

3.  Case Report on Calciphylaxis: An Early Diagnosis and Treatment May Improve Outcome.

Authors:  Barbara J Marshall; Rachel E Johnson
Journal:  J Am Coll Clin Wound Spec       Date:  2013-11-12

Review 4.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

Review 5.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 6.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

7.  Comparison of Safety Profiles of New Oral Anticoagulants with Warfarin Using the Japanese Spontaneous Reporting Database.

Authors:  Keiko Hosohata; Saki Oyama; Iku Niinomi; Tomohito Wakabayashi; Ayaka Inada; Kazunori Iwanaga
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

Review 8.  The emerging role of phosphate in vascular calcification.

Authors:  Cecilia M Giachelli
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

Review 9.  Secondary and tertiary hyperparathyroidism, state of the art surgical management.

Authors:  Susan C Pitt; Rebecca S Sippel; Herbert Chen
Journal:  Surg Clin North Am       Date:  2009-10       Impact factor: 2.741

10.  Calciphylaxis in chronic renal failure: An approach to risk factors.

Authors:  W Rezaie; H A J M Overtoom; M Flens; R J L Klaassen
Journal:  Indian J Nephrol       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.